

Astrid O Kittang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8693385/publications.pdf>

Version: 2024-02-01

20
papers

726
citations

623734

14
h-index

752698

20
g-index

20
all docs

20
docs citations

20
times ranked

969
citing authors

#	ARTICLE	IF	CITATIONS
1	Novel variants in Nordic patients referred for genetic testing of telomere-related disorders. <i>European Journal of Human Genetics</i> , 2018, 26, 858-867.	2.8	14
2	The Systemic Profile of Soluble Immune Mediators in Patients with Myelodysplastic Syndromes. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1080.	4.1	16
3	Reduced potency of cytotoxic T lymphocytes from patients with high-risk myelodysplastic syndromes. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 1135-1147.	4.2	6
4	Expansion of myeloid derived suppressor cells correlates with number of T regulatory cells and disease progression in myelodysplastic syndrome. <i>Oncolmmunology</i> , 2016, 5, e1062208.	4.6	97
5	A 35-year-old woman with influenza A-associated thrombotic thrombocytopenic purpura. <i>Blood Coagulation and Fibrinolysis</i> , 2015, 26, 469-472.	1.0	7
6	Limited clinical efficacy of azacitidine in transfusion-dependent, growth factor-resistant, low- and Int-1-risk MDS: Results from the nordic NMDSG08A phase II trial. <i>Blood Cancer Journal</i> , 2014, 4, e189-e189.	6.2	48
7	The Possible Diagnostic and Prognostic Use of Systemic Chemokine Profiles in Clinical Medicine—The Experience in Acute Myeloid Leukemia from Disease Development and Diagnosis via Conventional Chemotherapy to Allogeneic Stem Cell Transplantation. <i>Toxins</i> , 2013, 5, 336-362.	3.4	29
8	Expression patterns of chemokine receptors on circulating T cells from myelodysplastic syndrome patients. <i>Oncolmmunology</i> , 2013, 2, e23138.	4.6	11
9	High-dose etoposide in allogeneic stem cell transplantation. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 70, 765-782.	2.3	13
10	The chemokine system in allogeneic stem-cell transplantation: a possible therapeutic target?. <i>Expert Review of Hematology</i> , 2011, 4, 563-576.	2.2	35
11	Primary human acute myelogenous leukemia cells release matrix metalloproteases and their inhibitors: release profile and pharmacological modulation. <i>European Journal of Haematology</i> , 2010, 84, 239-251.	2.2	50
12	The Protein Kinase C Agonist PEPO05 (Ingenol 3-Angelate) in the Treatment of Human Cancer: A Balance between Efficacy and Toxicity. <i>Toxins</i> , 2010, 2, 174-194.	3.4	58
13	Targeting the angiopoietin (Ang)/Tie-2 pathway in the crosstalk between acute myeloid leukaemia and endothelial cells: studies of Tie-2 blocking antibodies, exogenous Ang-2 and inhibition of constitutive agonistic Ang-1 release. <i>Expert Opinion on Investigational Drugs</i> , 2010, 19, 169-183.	4.1	36
14	The protein kinase C agonist PEPO05 increases NF- κ B expression, induces differentiation and increases constitutive chemokine release by primary acute myeloid leukaemia cells. <i>British Journal of Haematology</i> , 2009, 145, 761-774.	2.5	26
15	In Vitro Induction of a Dendritic Cell Phenotype in Primary Human Acute Myelogenous Leukemia (AML) Blasts Alters the Chemokine Release Profile and Increases the Levels of T Cell Chemotactic CCL17 and CCL22. <i>Journal of Interferon and Cytokine Research</i> , 2008, 28, 297-310.	1.2	11
16	Anticancer Immunotherapy in Combination with Proapoptotic Therapy. <i>Current Cancer Drug Targets</i> , 2008, 8, 666-675.	1.6	18
17	Subclassification of patients with acute myelogenous leukemia based on chemokine responsiveness and constitutive chemokine release by their leukemic cells. <i>Haematologica</i> , 2007, 92, 332-341.	3.5	129
18	Cyclin B1 is commonly expressed in the cytoplasm of primary human acute myelogenous leukemia cells and serves as a leukemia-associated antigen associated with autoantibody response in a subset of patients. <i>European Journal of Haematology</i> , 2007, 79, 210-225.	2.2	31

#	ARTICLE	IF	CITATIONS
19	T lymphocyte chemotactic chemokines in acute myelogenous leukemia (AML): local release by native human AML blasts and systemic levels of CXCL10 (IP-10), CCL5 (RANTES) and CCL17 (TARC). <i>Cancer Immunology, Immunotherapy</i> , 2006, 55, 830-840.	4.2	43
20	Antiangiogenic Therapy in Acute Myelogenous Leukemia: Targeting of Vascular Endothelial Growth Factor and Interleukin 8 as Possible Antileukemic Strategies. <i>Current Cancer Drug Targets</i> , 2005, 5, 229-248.	1.6	48